Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338
recruitingphase_1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551

Clinical Trials (2)

Showing 2 of 2 trials
NCT07397338Phase 1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Recruiting
NCT06128551Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2